Related Experiment Video
Updated: May 12, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Dasatinib-induced nephrotic-range proteinuria
Eric Wallace1, William Lyndon, Phillip Chumley
1Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA. ericlwallace@uab.edu
Abstract:
Since the introduction of imatinib, tyrosine kinase inhibition has been a mainstay in the treatment of many malignancies. The number of these medications is growing, as are the number of targeted tyrosine kinases. Off-target effects of these medications can have beneficial or adverse effects on the kidney. The onus of knowing the implications of these medications on kidney function, and appropriate treatment when such adverse effects occur, is on the nephrologist. We present a patient with chronic myelogenous leukemia who developed nephrotic-range proteinuria after initiation on dasatinib therapy that resolved after changing therapy to imatinib. The mechanism of kidney injury caused by dasatinib has not been described previously in the literature. We provide a review of vascular endothelial growth factor and its pharmacologic inhibition as it pertains to kidney pathology and propose possible mechanisms by which dasatinib induces kidney injury.
Insights
Tyrosine kinase inhibitors (TKIs) like dasatinib can cause kidney damage, including nephrotic-range proteinuria. Switching to imatinib resolved the patient's kidney injury, highlighting the need for nephrologists to monitor TKI side effects.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) are crucial in treating malignancies, targeting specific kinases.
- The expanding use of TKIs necessitates understanding their potential off-target effects on kidney function.
- Nephrologists must be aware of and manage TKI-induced kidney pathologies.
Observation:
- A patient with chronic myelogenous leukemia developed nephrotic-range proteinuria after starting dasatinib.
- The proteinuria resolved upon discontinuation of dasatinib and initiation of imatinib therapy.
- This case highlights a previously undescribed mechanism of kidney injury associated with dasatinib.
Findings:
- Dasatinib therapy was associated with the development of nephrotic-range proteinuria.
- Switching to imatinib led to the resolution of proteinuria, suggesting a drug-specific effect.
- The study reviews the role of vascular endothelial growth factor (VEGF) in kidney pathology related to TKI therapy.
Implications:
- This case underscores the importance of vigilant renal monitoring in patients receiving TKIs.
- Understanding the mechanisms of TKI-induced kidney injury is crucial for appropriate management.
- Further research into the specific nephrotoxic pathways of drugs like dasatinib is warranted.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Diabetic Nephropathy
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
